Glenmark Pharmaceuticals shareholding pattern

·Pharma & Health Chart ›

Who owns itSep 2026 quarter

Promoters46.65%no change

Foreign investors (FII)21.51%+0.62 pts

Domestic institutions (DII)17.64%−0.96 pts

of which mutual funds15.61%−1.15 pts

of which insurance companies0.84%

Public14.17%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLENMARK₹2,300.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹64,906 Cr

Holding % of Total Shares 12 Months Ending	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Promoter & Group	46.65	46.65	46.65	46.65	46.65	46.65	46.65	46.65	46.65	46.65
FII / FPI	20.98	23.05	23.51	23.16	20.62	20.73	19.20	20.34	20.89	21.51
DII	13.92	13.21	13.85	14.60	17.64	18.61	20.09	19.29	18.60	17.64
Mutual Funds	10.92	11.41	12.12	12.86	15.55	16.31	17.86	16.80	16.76	15.61

Latest: 2026-09-30 · 60 quarters of history · click a row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.